MitoCare will begin in January 2011 and will be conducted by a 16 partner consortium led by Trophos.
MitoCare will evaluate the safety and efficacy of TRO40303 in a Phase II proof-of-concept study to treat cardiac ischemia-reperfusion injury (IRI) in acute myocardial infarction (MI) patients.
The study will also develop knowledge of biomarkers and models of cardiac ischemia-reperfusion injury.
The study will involve acute MI patients with large myocardial infarct undergoing coronary angioplasty, who will be administered with TRO40303 as a single IV infusion prior to the reperfusion by angioplasty.
TRO40303 is the second of Trophos’ proprietary cholesterol oxime mitochondrial pore modulators, whose mechanism of action involves prevention of stress-induced mitochondrial permeability transition, a target implicated in cardiac reperfusion injury.